p27 and p21 in gene therapies

Details p27 and p21 in gene therapies p27 and p21 in gene therapies

2001-03-09

2008-12-09

Ketter, James S (Department: 1636)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Primate cell, per se

C435S373000, C435S377000

Reexamination Certificate

active

07462483

ABSTRACT:
The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21cip1/waf1and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity, stem cells move into the cell cycle and proliferate without losing their pluripotentiality (i.e., their ability to differentiate into the various cell lines found in the blood stream). Any type of stem cell or progenitor cell, or precursor thereof, including, but not limited to, hematopoietic, gastrointestinal, lung, neural, skin, muscle, cardiac muscle, renal, mesenchymal, embryonic, fetal, or liver cell may be used in accordance with the invention. The present invention provides a method of expanding a cell population, cells with decreased p27 and/or p21 activity, transgenic animals with a disrupted p27 and/or p21 gene, pharmaceutical compositions comprising the cells of the invention, and methods of using these cells in gene therapy (e.g., stem cell gene therapy) and bone marrow transplantation.

REFERENCES:
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264564 (1993-11-01), Matteucci
patent: 5958769 (1999-09-01), Roberts et al.
patent: WO 97/26327 (1997-07-01), None
patent: WO 97/38091 (1997-10-01), None
Waldman et al. p21 is necessary for the p53 mediated G-1 arrest in human cancer cells Cancer Research vol. 55 1995 (previously cited).
Branch A good antisense is hard to find. TIBS vol. 23 pp. 45-50 1998.
Cheng Oncogene (2004) 7256-7266.
Stojkovic et al. Reproduction (Sep. 2004) 128(93) 259-67.
Zhu et al. Current Drug Targets (Feb. 2005) 6(1) 97-110.
Czyz et al. Biol. Chem., vol. 384, pp. 1391-1409 2003.
Waldman, et al., “p21 Is Necessary for the p53-Mediated G1Arrest in Human Cancer Cells”,Cancer Research, 55: 5187-5190, 1995.
International Search Report issued for corresponding PCT application PCT/US01/07538.
Asiedu, et al., Complex Regulation of CDK2 During Phorbol Ester-Induced Hematopoletic Differentiation,Blood, 90: 3430-3437, 1997.
Becker, et al., “Adhesion Receptor Expression by Hematopoietic Cell Lines and Murine Progenltors: Modulation by Cytokines and Cell Cycle Status”,Exp. Hematal, 27: 533-541, 1999.
Berardi, et al., “Functional Isolation and Characterization of Human Hematopoictic Stem Cells”,Science, 267: 104-108, 1995.
Braun, et al., “A Positive Effect of p21cip1/waf1in the Colony Formation from Murine Myeloid Progenitor Cells as Assessed by Retroviral-Mediated Gene Transfer”Blood Cells Mol. Dis.24: 138-148, 1998.
Brugarolas, et al., “Radiation-Induced Cell Cycle Arrest Compromised by p21 Deficiency”Nature, 377: 552-557, 1995.
Carver-Moore, et al., “Low Levels of Erythroid and Myeloid Progenitors in Thromboppoietin- and c-mpl-deficient mice”,Blood, 88: 803-808, 1996.
Chan, et al., “Triplex DNA: Fundamentals, Advances, and Potential Applications for Gene Therapy”J. Mol. Med., 75(4): 267-282, 1997.
Cheng, et al., Hematopoictic Stem Cell Qulescence Maintained by p21(cip1/waf1),Science, 287: 1804-1808, 2000.
Cheng, et al., “Temporal Mapping of Gene Expression Levels During the Differentiation of Individual Primary Hematopoietic Cells”,Proc. Natl. Acad. Sci. USA, 93, 13158-13163, 1996.
Coats, et al., “Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle”.Science: 272: 877-880, 1996.
Crooke, “Molecular Mechanisms of Action of Antisense Drugs”,Biochim. Biophys. Acta, 1489(1): 31-44, 1999.
Cunto, et al., “Inhibitory Function of p21Cip1/WAF1in Differentiation of Primary Mouse Keratinocytes Independent of Cell Cylce Control”,Science, 280:1069, 1998.
Dao, et al., “Reduction in Levels of the Cyclin-Dependent Kinase Inhibitor p27(kip-1) Coupled with Transforming Growth Factor Beta Neutralization Induces Cell-Cycle Entry and Increases Retroviral Transduction of Primitive Human Hematopoietic Cells”Proc. Natl. Acad. Sci. USA, 95: 13006-13011, 1998.
Deng, et al., “Mice Lacking p21Cip1/WAF1Undergo Normal Development, But Are Defective in G1 Checkpoint Control”Cell, 82: 675-684, 1995.
Drize, et al., “Local Clonal Analysis of the Hematopoietic System Shows That Multiple Small Short-Living Clones Maintain Life-Long Hematopoiesis in Reconstituted Mice”Blood, 88: 2927-2938, 1996.
Durand, et al., p27kip1 Alters the Response of Cells to Miltogen and is Part of a Cell-Intrinsic Timer that Arrests the Cell Cycle and Initiates Differentiation:,Curr. Biol.8: 431-440, 1998.
Fadok, et al., Exposure of Phosphatidylscrine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages,J. Immunol.148: 2207-2216, 1992.
Fero, et al., A Syndrome of Multiorgan Hyperplasia with Features of Glgantism Tumorlgenesis, and Female Sterility in p27 (kip1)-Deficient Mice Cell 85:733-744, 1996.
Gardner, et al., “Hematopoictic Precursor Cell Exhaustion in a Cause of Proliferative Defect in Primitive Stem Cells (PHSC) After Chemotherapy. Exp. Hermatol.” Exp. Hermatol, 25: 495-501, 1997.
Gothot, et al., “Functional Heterogeneity of Human CD34(+) Cells Isolated in Subcompartments of the GO/G1 Phase of the Cell Cycle”,Blood, 90: 4384-4393, 1997.
Gothot, et al., Assessment of Proliferative and Colony-Forming Capacity After Successive in Vitro Divisions of Single Human CD34+Cells Initially Isolated in G0Exp. Hermatol.26: 562, 1998.
Grzegorzewski, et al., “Recombinant Transforming Growth Factor Beta 1 and Beta 2 Protect Mice From acutely Lethal Doses of 5-Fluorouracil and Doxorubicin”,J. Exp. Med.180: 1047-1057, 1994.
Harrison, et al., “Loss of Proliferative Capacity in Immunohemopoietic Stem Cells Caused by Serial Transplantation Rather Than Aging”,J. Exp. Med.147: 1526-1531, 1978.
Harrison, D.E., Competitive Repopulation: A New Assay For Long-Term Stem Cell Functional Capacity,Blood, 55: 77-81, 1980.
Harrison, et al., Loss of Stem Cell Repopulating Ability Upon Transplantation,J. Exp. Med.156: 1767-1779, 1982.
Hengst, et al., “Translational Control of p27Kip1 Accumulation During the Cell Cycle,”Science, 271: 1861-1864, 1996.
Holyoake, “Isolation of a Highly Quiescent Subpopulation of Primitive Leukkemic Cells in Chronic Myeloid Leukemia” et al.,Blood, 94: 2056-2064, 1999.
Kiyokawa, et al., Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27(Kip1).Cells, 85, 721-732, 1996.
Kranenburg, et al., “Inhibition of Cyclin-Dependent Kinase Activity Triggers Neuronal Differentiation of Mouse Neuroblastoma Cells”,J. Cell Biol.131: 227-234, 1995.
LaBaer, et al., “New Functional Activities for the p21 Family of CDK Inhibitors”,Genes Dev.11: 847-862, 1997.
Leemhuis, et al., “Isolation of Primitive Human Bone Marrow Hematopoietic Progenitor Cells Using Hoechst 33342 and Rhodamine 123”,Exp. Hematol.24: 1215-1224, 1996.
Lerner, et al., “5-Fluorouracil Spares Hematopoietic Stem Cells Responsible for Long-Term Repopulation”Exp. Hematol.18: 114-118, 1990.
Liu, et al., Transcriptional Activation of the Human p21 (WAF1/CIP1) Gene by Retinoic Acid Receptor. Correlation with Retinoid Induction of U937 Cell Differentiation.J. Biol. Chem.271(49): 31723-31728, 1996.
Mantel, et al., Involvement of p21cip1 and p27kip-1 in the Molecular Mechanisms of Steel Factor-Induced Proliferative Synergy in Vitro and of p21cip in the Maintenance of Stem/Progenitor Cells in Vivo.Blood, 88: 3710-3719, 1996.
Mauch, et al., Hematopoictic Stem Cell Compartment: Acute and Late Effects of Radiation Therapy and Chemotherapy,Int. J. Radiat. Oncol. Biol. Phys.31: 1319-1339, 1995.
Müller, et al., “Genetic Control of the Frequency of Hematopoietic Stem Cells in Mice: Mapping of a Candidate Locus to Chromosome1”J. Exp. Med.183: 1141-1150, 1996.
Müller, e

Affiliated with

Also associated with

Rating

p27 and p21 in gene therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with p27 and p21 in gene therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and p27 and p21 in gene therapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4027559